Canadian Halal Investor.

NYSE Shariah screener · October 2026

Is McKesson Corporation (MCK) Halal?

PASS

McKesson Corporation · NYSE: MCK · Healthcare

The short answer

Yes - McKesson Corporation (MCK) passes this Shariah stock screen at all three gates. McKesson, the Irving-based healthcare services company, earns its revenue from pharmaceutical distribution, oncology and multispecialty services, prescription technology, and medical-surgical supplies (FY2026 revenues $403,430M) - none of which involve alcohol, tobacco, gambling, weapons, adult entertainment, pork, or conventional finance as a core activity. The financial ratios pass: total debt of $6,526M is about 6.56% of its ~$99.52B market cap ($898.82/share, October 2026), below the ~33% ceiling, and interest income of $179M is about 0.044% of revenue, below the 5% ceiling. Zoya and ShariaPortfolio independently rate McKesson Shariah-compliant / Shariah Compliant. This is a factual screen, not a religious ruling - consult a qualified scholar for personal rulings.

Gate 1 — Business activity: PASS

McKesson Corporation (NYSE: MCK), founded in 1833 and headquartered in Irving, Texas, is a diversified healthcare services company. Per its Form 10-K for the fiscal year ended March 31, 2026 (filed May 8, 2026; accession 0000927653-26-000069; auditor Deloitte & Touche), it reports four segments: North American Pharmaceutical (wholesale distribution of branded, generic, specialty, biosimilar and OTC pharmaceuticals, including the ClarusONE generic-sourcing JV with Walmart), Oncology & Multispecialty (specialty drug distribution, infusion services, direct-to-patient pharmacy, cell/gene therapy, the U.S. Oncology Network), Prescription Technology Solutions (prior authorization, price transparency, benefit insight, dispensing support), and Medical-Surgical Solutions (medical-surgical supplies to non-acute US settings). Business-screen implication (factual): healthcare distribution and services - no alcohol, tobacco, gambling, weapons, adult entertainment, pork, or conventional finance as a core activity (zero 'tobacco' hits in the 10-K). Gate 1 passes. Facts only.

Gate 2 — Debt and cash: PASS

Per McKesson's Form 10-K for the fiscal year ended March 31, 2026 (filed May 8, 2026; accession 0000927653-26-000069; $ millions), total debt at March 31, 2026 was: current portion of long-term debt $1,267M + long-term debt $5,259M = $6,526M. Against a market cap of about $99.52B ($898.82 per share, Finnhub, October 2026; sanity check: 120,204,051 shares outstanding at April 30, 2026 x $898.82 = about $108.04B - same ballpark), debt / market cap is about 6.56% - below the ~33% ceiling. Cash and cash equivalents of $3,975M is about 3.99% of market cap. Footnote: the stockholders' deficit (-$2,172M) is a buyback artifact (treasury shares $32,005M), not insolvency - operating cash flow was $6.155B in FY2026. Gate 2 passes. Facts only.

Gate 3 — Non-compliant income: PASS

Per McKesson's Form 10-K for the fiscal year ended March 31, 2026 (filed May 8, 2026; accession 0000927653-26-000069; $ millions), interest income was $179M ($173M FY2025; $118M FY2024; from the Financial Notes - Other income, net of $236M = $179M interest + $7M equity in earnings + $6M equity-security gains + $44M other, net) against Revenues of $403,430M = about 0.044% of revenue - below the 5% non-compliant income ceiling. Interest expense was $247M. Zoya's MCK page independently quotes interest income of $179M on revenue of $403,430,000,000 (0.04%) - matching the 10-K exactly. Gate 3 passes. Facts only.

Key figures used

Frequently asked questions

What does McKesson do?

McKesson Corporation (NYSE: MCK), founded in 1833 and headquartered in Irving, Texas, is a diversified healthcare services company. Per its Form 10-K for the fiscal year ended March 31, 2026 (filed May 8, 2026; accession 0000927653-26-000069; auditor Deloitte & Touche), it reports four segments: North American Pharmaceutical (wholesale distribution of branded, generic, specialty, biosimilar and OTC pharmaceuticals, including the ClarusONE generic-sourcing JV with Walmart), Oncology & Multispecialty (specialty drug distribution, infusion services, direct-to-patient pharmacy, cell/gene therapy, the U.S. Oncology Network), Prescription Technology Solutions (prior authorization, price transparency, benefit insight, dispensing support), and Medical-Surgical Solutions (medical-surgical supplies to non-acute US settings). Its common stock trades on the New York Stock Exchange (ticker MCK). In FY2026 it reported revenues of $403,430M.

Why does McKesson pass this Shariah stock screen?

McKesson passes all three gates of this Shariah stock screen. Gate 1 (business activity): healthcare distribution and services - no alcohol, tobacco, gambling, weapons, adult entertainment, pork, or conventional finance as a core activity - a clean business (zero 'tobacco' hits in the 10-K). Gate 2 (debt): total debt of $6,526M is about 6.56% of its ~$99.52B market cap (October 2026), below the ~33% ceiling. Gate 3 (non-compliant income): interest income of $179M is about 0.044% of FY2026 revenues ($403,430M), below the 5% ceiling. Result: PASS. This is a factual screen, not a religious ruling - consult a qualified scholar for personal rulings.

What is McKesson's interest-bearing debt ratio?

Per McKesson's Form 10-K for the fiscal year ended March 31, 2026 (filed May 8, 2026; accession 0000927653-26-000069; $ millions), total debt at March 31, 2026 was: current portion of long-term debt $1,267M + long-term debt $5,259M = $6,526M. Against a market cap of about $99.52B ($898.82 per share, Finnhub, October 2026; sanity check: 120,204,051 shares outstanding at April 30, 2026 x $898.82 = about $108.04B - same ballpark), debt / market cap is about 6.56% - below the ~33% ceiling. Cash and cash equivalents of $3,975M is about 3.99% of market cap. Footnote: the stockholders' deficit (-$2,172M) is a buyback artifact (treasury shares $32,005M), not insolvency - operating cash flow was $6.155B in FY2026. Gate 2 passes. Facts only.

How much interest income does McKesson earn?

Per McKesson's Form 10-K for the fiscal year ended March 31, 2026 (filed May 8, 2026; accession 0000927653-26-000069; $ millions), interest income was $179M ($173M FY2025; $118M FY2024; from the Financial Notes - Other income, net of $236M = $179M interest + $7M equity in earnings + $6M equity-security gains + $44M other, net) against Revenues of $403,430M = about 0.044% of revenue - below the 5% non-compliant income ceiling. Interest expense was $247M. Zoya's MCK page independently quotes interest income of $179M on revenue of $403,430,000,000 (0.04%) - matching the 10-K exactly. Gate 3 passes. Facts only.

Do Zoya, Musaffa, or ShariaPortfolio cover McKesson?

Zoya covers McKesson at zoya.finance/stocks/mck: 'As of September 2026, MCK is Shariah-compliant and therefore considered halal to invest in,' quoting interest income of $179M on revenue of $403,430,000,000 (0.04%) - matching the 10-K exactly. ShariaPortfolio covers MCK at spscreener.mxcorporate.com/ticker/mck-mckesson-corp/: 'McKesson Corp is Shariah Compliant. It passes 4/5 Shariah standards we screen against.' Musaffa: no current musaffa.com/stock/MCK/ page was found via search; only a ~7-month-old Musaffa Academy article lists 'Mckesson Corp (MCK)' as Halal - honestly reported as partial/older coverage, not a current direct rating. MuslimXChange (a separate AAOIFI-certified screener, not Musaffa) covers MCK at muslimxchange.com/ticker/mck/: 'Yes, MCK (McKesson Corp) stock is Shariah compliant.'

Sources

Screened 2026-10-02 from published company figures and market data. Figures change; this page is educational, not financial advice and not a religious ruling.

Screened with our two-gate Shariah screening methodology (business-activity gate, then AAOIFI-style financial ratios).